The Queue Before the Panel: Prioritising Multiplex Respiratory PCR When Winter Demand Outruns Capacity

Multiplex respiratory PCR has become a default winter tool in UK microbiology, but its clinical value depends on a constraint that is easy to forget: every additional target consumes extraction capacity, analyst time and interpretive attention. In the 2026/27 season, the pressure is not simply a rise in requests. It is the combination of broader panels, higher expectations and a finite bench. A triage model is therefore not an administrative luxury. It is a clinical governance requirement.

Begin With the Clinical Question, Not the Panel Menu

The first control point sits before a sample reaches the laboratory: the request itself. Laboratories should define, with clinical colleagues, a small number of access tiers that reflect what a result will change. A useful starting distinction is between requests that inform immediate infection control or treatment decisions and those that support retrospective diagnosis or surveillance.

Critically ill patients, admissions through emergency departments, immunocompromised patients, paediatric inpatients and suspected outbreaks in closed settings belong in the highest tier. So do requests that will determine cohorting, isolation or antiviral use. Routine community requests can remain important without being urgent. The distinction should be written into the request form and the laboratory standard operating procedure, not left to individual judgement at the bench.

A simple prompt on electronic requesting can do much of the work: will this result alter management within the next 24 hours? Where the answer is no, the request may still be appropriate, but it can wait in a planned queue. The aim is not to refuse testing. It is to make the queue legible.

Panel Breadth Is a Capacity Decision

Multiplex assays encourage a tempting assumption: if the platform can detect twenty targets, every request should receive all twenty. In a pressured winter, that assumption becomes a capacity leak. Panel breadth should be matched to the clinical setting, the patient group and the season.

laboratories should consider staged or reflex testing for lower-risk community requests, reserving the fullest panel for severe disease, immunocompromise, suspected outbreak investigation and cases where a broad differential is genuinely active. A winter mini-panel covering influenza, respiratory syncytial virus and SARS-CoV-2 may answer the immediate question for many primary care patients, with extension to broader targets when the clinical picture or public health context justifies it.

The decision should be reviewed weekly against positivity, turnaround time and clinical feedback. Panel creep is rarely a single dramatic choice. It accumulates through convenience, habit and the understandable wish to avoid a second sample. Once embedded, it is difficult to reverse.

Turnaround Time Is a Promise With Conditions

Turnaround time is often quoted as a single number, usually from receipt in the laboratory. Clinicians hear something simpler: when will the result be available? The gap between those two statements causes avoidable friction.

Laboratories should publish category-specific expectations, including the clock start, the proportion of tests completed within target and the route for urgent escalation. A median figure alone is insufficient. A service that reports a median of 18 hours but a 90th percentile of 40 hours is not delivering the same promise as one with a tighter distribution.

During winter pressure, batching may be necessary. If so, say so. A clear statement that urgent inpatient samples are run throughout the day while routine community samples are batched overnight is more useful than an aspirational target that cannot be met. The ward can plan around an honest timetable. It cannot plan around a silent delay.

Read the Result Inside Its Limits

No triage model will protect clinical credibility if results are over-interpreted. Detection is not the same as disease. Co-detections are common, particularly in children and in patients with prolonged shedding. A positive signal for one target does not automatically explain the illness, and a negative result does not exclude infection when the sample is poor or taken late.

Ct values are assay-specific and should not be compared across platforms as if they were standardised measures of infectiousness. Laboratories should provide concise interpretive comments where local policy allows, and should resist the temptation to append broad advice that belongs to clinical teams. The most useful comment is often a reminder of the specimen type, the assay limitation and the need to interpret the result alongside the clinical picture.

This matters for antimicrobial stewardship as well as infection control. A multiplex result can narrow a differential, but it can also prompt unnecessary treatment if a detected target is assumed to be the sole cause of symptoms. The laboratory's language should be precise enough to support good decisions without pretending to make them.

Tell the Ward and the GP What the Service Can Bear

Capacity limits should be communicated before they become failures. A daily capacity statement, shared with acute trusts, community providers and local medical committees, can set expectations without disclosing patient information. It might state which request categories are being prioritised, the current expected turnaround for each and the escalation route for genuinely urgent cases.

General practice needs a different channel from the ward. A short bulletin through the integrated care system, primary care network or local pathology messaging service is more effective than a notice buried on an intranet page. The message should be plain: what to send, what to hold, what to telephone about and what will happen if demand exceeds the agreed threshold.

Make the Model Auditable

The triage model should be reviewed as a clinical service, not merely as a queue. Weekly monitoring should include category volumes, turnaround by tier, positivity, repeat requests, complaints and any safety events associated with delay. Equally, the laboratory should ask whether the model is being applied equitably across providers and patient groups.

A short post-season review, with wards, primary care and infection specialists, can identify where the tiers were too rigid or too porous. The output should be a revised procedure for the next winter, not a folder of data.

Multiplex respiratory PCR will remain a central tool for UK laboratories in 2026 and beyond. Its value depends on disciplined demand management, honest communication and interpretative restraint. The queue before the panel is where that discipline begins.